AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04140006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN Gel
Description: Flapped surgery for insertion of dental implant with topical application of ALN gel
Study NCT04140006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMP Gel
Description: Flapped surgery for insertion of dental implant with topical application of BMP gel
Study NCT04140006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Gel
Description: Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
Study NCT04140006 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Flapped surgery for insertion of dental implant without topical application of any gel
Study NCT01993420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRM02
Study NCT01993420 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01317732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOTIONPOD (TM) measures
Description: It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
Study NCT01832090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse® Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
Study NCT01832090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
Study NCT04403100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days
Study NCT04403100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ Ritonavir Oral Tablet
Description: tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
Study NCT04403100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
Description: Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days
Study NCT04403100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets - 01 tablet twice daily from day 01 through day 10.
Study NCT02934828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d\*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d\*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
Study NCT02934828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: postoperative chemotherapy
Description: postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
Study NCT01300845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Humidification
Description: From randomization, oxygen therapy is humidified
Study NCT01300845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Humidification
Description: oxygen therapy is never humidified
Study NCT00270374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Study NCT03440203 — intervention group
Intervention type: OTHER
Intervention: difficult activities of daily living in each group
Description: Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
Study NCT03520283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT03520283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03520283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: System Support Mapping
Description: Complete MAP
Study NCT01672346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVAI followed by adenosine provocation
Description: All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
Study NCT04051229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized isoenergetic high fat diet
Description: Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
Study NCT01478568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT01855126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light
Description: After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
Study NCT01855126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red light
Description: After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
Study NCT00418782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Study NCT00418782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-224535
Study NCT00418782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00398359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (physicians)
Description: Identifying and referring children with BMI >93%.
Study NCT00398359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification (families)
Description: Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
Study NCT01478568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desipramine
Description: oral
Study NCT02130206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries Free
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
Study NCT02130206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caries Active
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
Study NCT02130206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caries Free - Placebo
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
Study NCT02130206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caries Active - Placebo
Description: Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
Study NCT05359432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Receiving allocated drug dosage as per clinical needs
Study NCT05359432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Receiving allocated drug dosage as per clinical needs
Study NCT03201783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: immediate frozen-thawed embryo transfer
Description: Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
Study NCT03201783 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: delayed frozen-thawed embryo transfer
Description: Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
Study NCT01152281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maximal Control
Description: 30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
Study NCT01152281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental and Empowering
Description: Mix of Instrumental and empowering messages with stories of people living with HIV
Study NCT01152281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Control
Description: Control messages to increase awareness of HIV risk
Study NCT01152281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental
Description: Instrumental messages with stories of people living with HIV
Study NCT01152281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering
Description: Empowering messages with stories of people living with HIV
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STAI-Y scale for anxiety
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-Y scale for anxiety
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beck scale for depression
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck scale for depression
Study NCT02343887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without intervention
Study NCT04034602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration group
Description: plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
Study NCT00328874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Study NCT00328874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10
Study NCT01688037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 25 mg capsule
Study NCT01688037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: 50 mg capsule
Study NCT01688037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00368537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
Study NCT01920412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAmbre Left Atrial Appendage(LAA) Occluder
Description: Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
Study NCT00228436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study NCT03185611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Antibiotics
Study NCT03185611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: immunomodulator
Study NCT03863639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging Procedures
Description: Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures.
Study NCT03863639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Assessment Procedures
Description: Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
Study NCT03162653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
Study NCT03162653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
Study NCT00010335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
Study NCT00010335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD34 selection
Description: CD34+ cells are separated from the rest of the peripheral blood stem cells.
Study NCT02434146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Phenylephrine Solution
Description: Given topically via spray
Study NCT01932060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin Infusion
Description: Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
Study NCT01932060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Infusion
Description: Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
Study NCT04034602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo group
Description: the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
Study NCT00912275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib plus oral vinorelbine
Description: Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
Study NCT00281983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT01056471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells from adipose tissue.
Description: Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.
Study NCT03185611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: immunomodulator
Study NCT01056471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells from adipose tissue.
Description: Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
Study NCT00281983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00281983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT03668444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXS- Supportive Text Group
Description: TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
Study NCT03668444 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU- Treatment As Usual
Description: Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
Study NCT00086138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Zoloft)
Description: Sertraline: range of 25 to 125 mg per day for 24 weeks
Study NCT00086138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo designed to mimic sertraline taken daily for 24 weeks
Study NCT01760174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine bolus in transversus abdominis plane catheter
Description: Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours.
Study NCT01760174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain-infusion in epidural catheter
Description: Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours
Study NCT02915705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: burosumab
Description: solution for subcutaneous (SC) injection
Study NCT02915705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burosumab
Description: solution for subcutaneous (SC) injection
Study NCT03422874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
Study NCT03422874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
Study NCT03007927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Dexamethasone
Description: Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
Study NCT03007927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine- physiological solution
Description: Bupivacaine 1,5 mg/kg- physiological solution
Study NCT00281983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00281983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes